Press releases

Regulatory

December 10, 2021

Nanoform financial calendar for 2022

Regulatory

November 25, 2021

Nanoform Interim Report January – September 2021

Regulatory

November 17, 2021

Resolutions of Nanoform Finland Plc’s Extraordinary General Meeting on November 17, 2021

Non Regulatory

November 17, 2021

Nanoform wins Star of Innovation award at the European Small and Mid-Cap Awards 2021

Regulatory

November 15, 2021

Nanoform signs GMP agreement and achieves near-term business target

Non Regulatory

November 12, 2021

Nanoform receives ISO/IEC 27001:2013 certification for its Information Security Management System

Non Regulatory

November 11, 2021

Invitation to presentation of Nanoform’s Q3/2021 report on November 25, 2021

Regulatory

October 18, 2021

Nanoform convenes EGM to elect Jeanne Thoma as board member

Regulatory

October 18, 2021

Notice to the Extraordinary General Meeting of NANOFORM FINLAND PLC

Non Regulatory

September 29, 2021

Nanoform receives funding to solve challenges for global health

Regulatory

September 24, 2021

Nanoform Finland Plc – Manager’s transactions – Gonçalo Andrade

Non Regulatory

September 23, 2021

Nanoform shortlisted for the European Small and Mid-Cap Awards 2021

Non Regulatory

September 9, 2021

Nanoform technology delivers successful results for Herantis CDNF drug candidate

Regulatory

August 27, 2021

The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees

Regulatory

August 26, 2021

Nanoform Interim Report January – June 2021

Non Regulatory

August 12, 2021

Invitation to presentation of Nanoform’s Q2/2021 report on August 26, 2021

Non Regulatory

August 3, 2021

Nanoform and Boehringer Ingelheim execute master services agreement

Regulatory

June 14, 2021

Nanoform Finland Plc – Manager’s transactions – Gonçalo Andrade

Regulatory

June 11, 2021

The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees

Regulatory

June 11, 2021

Share subscriptions based on Nanoform Finland Plc’s multiple Stock Option Programs

Regulatory

June 2, 2021

Nanoform raises its mid-term business targets for 2025

Regulatory

May 27, 2021

Nanoform Interim Report January – March (Q1) 2021

Non Regulatory

May 25, 2021

Nanoform and Celanese Explore Ways to Enhance Drug Delivery

Regulatory

May 20, 2021

Cynthia Schwalm transitions to Senior Advisor Business Development US, from her role as member of the Board of Directors

Non Regulatory

May 18, 2021

Nanoform’s final clinical results confirm value proposition to the pharma industry

Non Regulatory

May 12, 2021

Invitation to presentation of Nanoform’s Q1/2021 report on May 27, 2021

Regulatory

May 11, 2021

The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees

Non Regulatory

April 21, 2021

Nanoform and Aprecia collaborate to advance 3D printed Nanomedicines

Regulatory

April 8, 2021

Nanoform Finland Plc – Manager’s transactions – Gonçalo Andrade

Regulatory

April 7, 2021

Share subscriptions based on Nanoform Finland Plc’s multiple Stock Option Programs

Regulatory

April 6, 2021

Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland Plc

Regulatory

April 6, 2021

Resolutions of Nanoform Finland Plc’s Annual General Meeting on April 6, 2021

Non Regulatory

March 31, 2021

Nanoform and Nacuity Pharmaceuticals Sign Technology Proof of Concept (“PoC”) Agreement for Two Ophthalmic Drug Candidates

Non Regulatory

March 22, 2021

Nanoform launches next-generation STARMAP^® v2.0, the AI-based drug candidate selection tool for CESS^®

Regulatory

March 10, 2021

NOTICE TO THE ANNUAL GENERAL MEETING OF NANOFORM FINLAND PLC

Regulatory

March 10, 2021

Nanoform Finland Plc: 5 633 803 new shares registered with the trade register

Regulatory

March 9, 2021

Nanoform Finland Plc successfully completes new share issue raising EUR 40 million

Regulatory

March 9, 2021

Nanoform Finland Plc announces its intention to carry out a new share issue to raise approximately EUR 40 million

Regulatory

February 26, 2021

Nanoform 1-12/2020 report and new company near-term target introduced

Regulatory

February 26, 2021

Nanoform sets new near-term business target for 2021 and 2022

Regulatory

February 24, 2021

Additional Positive Interim Results from Nanoform’s Clinical Study

Non Regulatory

February 12, 2021

Invitation to presentation of Nanoform’s year-end report for 2020 on February 26, 2021

Non Regulatory

February 9, 2021

Nanoform and Herantis sign Biologics Proof of Concept Agreement

Regulatory

January 22, 2021

Nanoform’s Clinical Study Indicates Positive Interim Results

Non Regulatory

January 11, 2021

Finnish Foundation for Share Promotion and Nasdaq Helsinki has chosen Nanoform as the company of the month (article in Finnish)

Regulatory

January 4, 2021

Nanoform sets a new near-term business target for 2021